Reversibility of effectively treated chemotherapy-related heart failure: Raising our awareness and a call to action for cardiology

Journal of Cardiac Failure

Volumn 20, Issue 3, 2014, Pages 159-160

  Lenihan, Daniel J ^a  

^a VANDERBILT UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CARDIOVASCULAR AGENT;

AWARENESS; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER PATIENT; CARDIOLOGY; CARDIOTOXICITY; CHEMOTHERAPY RELATED HEART FAILURE; EDITORIAL; HEART FAILURE; HEART LEFT VENTRICLE FAILURE; HEMATOLOGIC MALIGNANCY; HUMAN; PRIORITY JOURNAL; RISK ASSESSMENT; CHEMICALLY INDUCED; DRUG THERAPY; EARLY INTERVENTION; FEMALE; HEART LEFT VENTRICLE FUNCTION; MALE; NEOPLASMS; PROCEDURES;

ANTINEOPLASTIC AGENTS; CARDIOVASCULAR AGENTS; EARLY MEDICAL INTERVENTION; FEMALE; HUMANS; MALE; NEOPLASMS; VENTRICULAR DYSFUNCTION, LEFT;

EID: 84896067691     PISSN: 10719164     EISSN: 15328414     Source Type: Journal    
DOI: 10.1016/j.cardfail.2014.01.011     Document Type: Editorial

References (22)

1. E.J. Bowles, R. Wellman, and H.S. Feigelson et al. Risk of heart failure in breast cancer patients after anthracycline and trastuzumab treatment: a retrospective cohort study J Natl Ca 104 2012 1293 1305
2. J. Chen, J.B. Long, A. Hurria, C. Owusu, R.M. Steingart, and C.P. Gross Incidence of heart failure or cardiomyopathy after adjuvant trastuzumab therapy for breast cancer J Am Coll Cardiol 60 2012 2504 2512
3. H. Sawaya, I.A. Sebag, and J.C. Plana et al. Early detection and prediction of cardiotoxicity in chemotherapy-treated patients Am J Cardiol 107 2011 1375 1380
4. P. Thavendiranathan, A.D. Grant, T. Negishi, J.C. Plana, Z.B. Popovic, and T.H. Marwick Reproducibility of echocardiographic techniques for sequential assessment of left ventricular ejection fraction and volumes: application to patients undergoing cancer chemotherapy J Am Coll Cardiol 61 2013 77 84
5. D. Cardinale, A. Colombo, and R. Torrisi et al. Trastuzumab-induced cardiotoxicity: clinical and prognostic implications of troponin I evaluation J Clin Oncol 28 2010 3910 3916
6. B. Ky, and J.R. Carver Biomarker approach to the detection and cardioprotective strategies during anthracycline chemotherapy Heart Fail Clin 7 2011 323 331
7. S.C. Darby, M. Ewertz, and P. McGale et al. Risk of ischemic heart disease in women after radiotherapy for breast cancer N Engl J Med 368 2013 987 998
8. G.T. Armstrong, K.C. Oeffinger, and Y. Chen et al. Modifiable risk factors and major cardiac events among adult survivors of childhood cancer J Clin Oncol 31 2013 3673 3680
9. K.E. Henson, P. McGale, C. Taylor, and S.C. Darby Radiation-related mortality from heart disease and lung cancer more than 20 years after radiotherapy for breast cancer Br J Cancer 108 2013 179 182
10. D.J. Lenihan, and D.M. Cardinale Late cardiac effects of cancer treatment J Clin Oncol 30 2012 3657 3664
11. X. Bosch, M. Sitges, M. Rovira, J.T. Ortiz-Perez, and J. Esteve Enalapril and Carvedilol to prevent chemotherapy-induced left ventricular systolic dysfunction in patients with malignant hemopathies J Am Coll Cardiol 61 2013 2355 2362
12. N. Kalay, E. Basar, and I. Ozdogru et al. Protective effects of carvedilol against anthracycline-induced cardiomyopathy J Am Coll Cardiol 48 2006 2258 2262
13. L. Gianni, E.H. Herman, S.E. Lipshultz, G. Minotti, N. Sarvazyan, and D.B. Sawyer Anthracycline cardiotoxicity: from bench to bedside J Clin Oncol 26 2008 3777 3784
14. R. Kerkela, K.C. Woulfe, and J.B. Durand et al. Sunitinib-induced cardiotoxicity is mediated by off-target inhibition of AMP-activated protein kinase Clin Transl Sci 2 2009 15 25
15. M.L. Maitland, G.L. Bakris, and H.R. Black et al. Initial assessment, surveillance, and management of blood pressure in patients receiving vascular endothelial growth factor signaling pathway inhibitors J Natl Cancer Inst 102 2010 596 604
16. R.M. Steingart, G.L. Bakris, and H.X. Chen et al. Management of cardiac toxicity in patients receiving vascular endothelial growth factor signaling pathway inhibitors Am Heart J 163 2012 156 163
17. T.M. Suter, M. Procter, and D.J. van Veldhuisen et al. Trastuzumab-associated cardiac adverse effects in the herceptin adjuvant trial J Clin Oncol 25 2007 3859 3865
18. D. Lenihan, T. Suter, M. Brammer, C. Neate, G. Ross, and J. Baselga Pooled analysis of cardiac safety in patients with cancer treated with pertuzumab Ann Oncol 23 2012 791 800
19. A. Seidman, C. Hudis, and M.K. Pierri et al. Cardiac dysfunction in the trastuzumab clinical trials experience J Clin Oncol 20 2002 1215 1221
20. J.D. Groarke, S. Cheng, and J. Moslehi Cancer-drug discovery and cardiovascular surveillance N Engl J Med 369 2013 1779 1781
21. C.L. Chen, and R. Steingart Cardiac disease and heart failure in cancer patients: is our training adequate to provide optimal care? Heart Fail Clin 7 2011 357 362
22. American College of Cardiology. History. Available at: http://www.cardiosource.org/en/ACC/About-ACC/Who-We-Are/History.aspx. Accessed January 13, 2014.